# EDGAR Filing Document

**Accession Number:** 0001501796
**File Stem:** 0001193125-26-202563
**Filing Date:** 2026-5
**Character Count:** 22213
**Document Hash:** b2a084f7fd54ed219226bebd8024de83
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-202563.hdr.sgml**: 20260504

**ACCESSION NUMBER**: 0001193125-26-202563

**CONFORMED SUBMISSION TYPE**: S-3MEF

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260504

**DATE AS OF CHANGE**: 20260504

**EFFECTIVENESS DATE**: 20260504

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aura Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001501796
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 320271970
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-3MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-295515
- **FILM NUMBER:** 26934648

**BUSINESS ADDRESS:**
- **STREET 1:** 80 GUEST STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02135
- **BUSINESS PHONE:** (617)500-8864

**MAIL ADDRESS:**
- **STREET 1:** 80 GUEST STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02135

**As filed with the Securities and Exchange Commission on May 4, 2026.** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-3** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Aura Biosciences, Inc.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **32-0271970** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification Number)** |

---

**80 Guest Street** 

**Boston, MA 02135** 

**(617) 500-8864** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Natalie Holles** 

**Chief Executive Officer and President** 

**Aura Biosciences, Inc. 80 Guest Street** 

**Boston, MA 02135** 

**(617) 500-8864** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***With copies to:***

**Danielle Lauzon, Esq.** 

**Stephanie A. Richards, Esq.** 

**Goodwin Procter LLP** 

**100 Northern Avenue** 

**Boston, MA 02210** 

**Telephone: (617) 570-1000**

**Approximate date of commencement of proposed sale to the public:** From time to time after this registration statement becomes effective.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ 333-278253

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**The Registration Statement shall become effective upon filing in accordance with Rule 462(b) under the Securities Act of 1933, as amended.** 

------

**EXPLANATORY NOTE AND INCORPORATION OF** 

**CERTAIN INFORMATION BY REFERENCE** 

Pursuant to Rule 462(b) under the Securities Act of 1933, as amended, Aura Biosciences, Inc. (the "Registrant") is filing this Registration Statement on Form S-3 (this "Registration Statement") with the Securities and Exchange Commission (the "Commission"). This Registration Statement relates to the public offering of securities contemplated by the Registration Statement on Form S-3 (File No. 333-278253) (the "Prior Registration Statement"), which the Registrant initially filed with the Commission on March 27, 2024, and which the Commission declared effective on April 5, 2024.

The Registrant is filing this Registration Statement for the sole purpose of increasing the aggregate amount of securities offered by the Registrant by a proposed aggregate offering price of $49,907,450.00, which includes shares that may be sold by the Registrant in the event the underwriters exercise their option to purchase additional shares of the Registrant's common stock. The additional securities that are being registered for issuance and sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price of unsold securities under the Prior Registration Statement. The information set forth in the Prior Registration Statement and all exhibits to the Prior Registration Statement are hereby incorporated by reference into this Registration Statement.

The required opinion and consents are listed on the Exhibit Index below and filed herewith or incorporated by reference herein.

------

**PART II** 

**INFORMATION NOT REQUIRED IN PROSPECTUS** 

**Item 16.** **Exhibits** <br>

All exhibits filed with or incorporated by reference in the Registration Statement on Form S-3 (File No. 333-278253) are incorporated by reference into, and shall be deemed a part of, this Registration Statement, and the following additional exhibits are filed herewith, as part of this Registration Statement:

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 5.1 | [Opinion of Goodwin Procter LLP.](d61055dex51.htm) |
| 23.1 | [Consent of Ernst & Young LLP Independent Registered Public Accounting Firm.](d61055dex231.htm) |
| 23.2 | [Consent of Goodwin Procter LLP (see Exhibit 5.1).](d61055dex51.htm) |
| 24.1 | [Power of Attorney (incorporated by reference to Exhibit 24.1 to the Prior Registration Statement).](d61055ds3mef.htm#sig) |
| 107 | [Filing Fee Table.](d61055dexfilingfees.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement on Form S-3 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on the 4th day of May, 2026.

---

| | |
|:---|:---|
| **Aura Biosciences, Inc.** | **Aura Biosciences, Inc.** |
| By: | /s/ Anthony Gibney |
|  | Anthony Gibney |
|  | Chief Financial and Business Officer |

---

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signatures** | **Title** | **Date** |
| /s/ Natalie Holles<br> Natalie Holles | Chief Executive Officer and President<br> (*Principal Executive Officer*) | May 4, 2026 |
| /s/ Anthony Gibney<br> Anthony Gibney | Chief Financial and Business Officer<br> *(Principal Financial Officer)* | May 4, 2026 |
| /s/ Amy Elazzouzi<br> Amy Elazzouzi | Senior Vice President, Finance<br> *(Principal Accounting Officer)* | May 4, 2026 |
|  |  | May 4, 2026 |
| /s/ David Johnson<br> David Johnson | Director | May 4, 2026 |
| /s/ Teresa Bitetti<br> Teresa Bitetti | Director | May 4, 2026 |
|  |  | May 4, 2026 |
| /s/ Giovanni Mariggi<br> Giovanni Mariggi | Director | May 4, 2026 |
| /s/ Antony Mattessich<br> Antony Mattessich | Director | May 4, 2026 |
|  |  | May 4, 2026 |
| /s/ Sapna Srivastava<br> Sapna Srivastava | Director | May 4, 2026 |
| /s/ Karan Takhar<br> Karan Takhar | Director | May 4, 2026 |

---

## Exhibit 5.1

**Exhibit 5.1** 

---

| | |
|:---|:---|
| ![LOGO](g61055g0502232710786.jpg) | Goodwin Procter LLP<br> 100 Northern Avenue<br> Boston, MA 02210<br>goodwinlaw.com<br> +1 617 570 1000 |

---

May 4, 2026

Aura Biosciences, Inc.

80 Guest Street

Boston, MA 02135

Re: <u>Securities Being Registered under Registration Statement on Form S-3</u>

We have acted as counsel to you in connection with your filing of (i) a Registration Statement on Form S-3 (File No. 333-278253) (as amended or supplemented, the "Initial Registration Statement") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), and (ii) a Registration Statement on Form S-3 filed pursuant to Rule 462(b) promulgated under the Securities Act relating to the Initial Registration Statement (the "462(b) Registration Statement" and, together with the Initial Registration Statement, the "Registration Statement"), relating to the offering by Aura Biosciences, Inc., a Delaware corporation (the "Company"), of up to $49,907,450 of (i) the Company's common stock, par value $0.00001 per share (the "Common Stock"), (ii) pre-funded warrants to purchase shares of Common Stock (the "Pre-Funded Warrants") and (iii) shares issuable upon the exercise of Pre-Funded Warrants (such shares, the "Warrant Shares" and, together with the Common Stock and Pre-Funded Warrants, the "Securities").

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinions set forth below, on certificates of officers of the Company.

The opinions set forth below are limited to the Delaware General Corporation Law and the law of New York.

For purposes of the opinions set forth below, without limiting any other exceptions or qualifications set forth herein, we have assumed that (i) the Pre-Funded Warrants, the warrant agreements, and other agreements governing Securities offered pursuant to the Registration Statement will be governed by the internal law of New York and (ii) after the issuance of any Securities offered pursuant to the Registration Statement, the total number of issued shares of Common Stock, together with the total number of shares of such stock issuable upon the exercise, exchange, conversion or settlement, as the case may be, of any exercisable, exchangeable or convertible security as the case may be, then outstanding, will not exceed the total number of authorized shares of Common Stock then available for issuance under the Company's certificate of incorporation as then in effect (the "Charter").

------

Aura Biosciences, Inc.

May 4, 2026

For purposes of the opinions set forth below, we refer to the following as the "Future Approval and Issuance" of Securities:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• with respect to any of the Securities, (a) the approval by the Company of the amount, terms and issuance of
such Securities (the "Approval") and (b) the issuance of such Securities in accordance with the Approval upon the receipt by the Company of the consideration (which, in the case of shares of Common Stock, is not less than the par
value of such shares) to be paid in accordance with the Approval; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• with respect to the Pre-Funded Warrants, (a) the approval, execution
and delivery by the Company and any other parties thereto of any agreement under which the Pre-Funded Warrants are to be issued, and (b) the establishment of the terms of the Pre-Funded Warrants and the issuance of the Pre-Funded Warrants in conformity with those terms, the terms of any applicable agreement and applicable law.

Based upon the foregoing, and subject to the additional qualifications set forth below, we are of the opinion that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Upon the Future Approval and Issuance of shares of Common Stock, such shares of Common Stock will be validly
issued, fully paid and nonassessable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Upon the Future Approval and Issuance of the Pre-Funded Warrants, such Pre-Funded Warrants will be valid and binding obligations of the Company.

The opinions expressed above are subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws of general application affecting the rights and remedies of creditors and to general principles of equity.

This opinion letter and the opinions it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 Business Lawyer 815 (Summer 2019).

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the 462(b) Registration Statement and to the references to our firm under the caption "Legal Matters" in the Initial Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

------

Aura Biosciences, Inc.

May 4, 2026

---

| |
|:---|
| Very truly yours, |
| /s/ Goodwin Procter LLP |
| GOODWIN PROCTER LLP |

---

## Exhibit 23.1

**Exhibit 23.1** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the reference of our firm under the caption "Experts" in the Registration Statement on Form S-3 (No. 333-278253) and to the incorporation by reference of our report dated March 30, 2026, with respect to the consolidated financial statements of Aura Biosciences, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Boston, Massachusetts

May 4, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

#### Calculation of Filing Fee Tables

#### S-3

#### Aura Biosciences, Inc.
Table 1: Newly Registered and Carry Forward Securities ☐ Not Applicable

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Security<br>Type | Security<br>Class<br>Title | Fee<br>Calculation<br>or Carry<br>Forward<br>Rule | Amount<br>Registered | Proposed<br>Maximum<br>Offering<br>Price Per<br>Unit | Maximum<br>Aggregate<br>Offering<br>Price | Fee<br>Rate | Amount of<br>Registration<br>Fee | Carry<br>Forward<br>Form<br>Type | Carry<br>Forward<br>File<br>Number | Carry<br>Forward<br>Initial<br>Effective<br>Date | Filing Fee<br>Previously<br>Paid in<br>Connection<br>with Unsold<br>Securities to<br>be Carried<br>Forward |
| &nbsp;&nbsp;&nbsp;Newly Registered Securities | &nbsp;&nbsp;&nbsp;Newly Registered Securities | &nbsp;&nbsp;&nbsp;Newly Registered Securities | &nbsp;&nbsp;&nbsp;Newly Registered Securities | &nbsp;&nbsp;&nbsp;Newly Registered Securities | &nbsp;&nbsp;&nbsp;Newly Registered Securities | &nbsp;&nbsp;&nbsp;Newly Registered Securities | &nbsp;&nbsp;&nbsp;Newly Registered Securities | &nbsp;&nbsp;&nbsp;Newly Registered Securities | &nbsp;&nbsp;&nbsp;Newly Registered Securities | &nbsp;&nbsp;&nbsp;Newly Registered Securities | &nbsp;&nbsp;&nbsp;Newly Registered Securities | &nbsp;&nbsp;&nbsp;Newly Registered Securities |
|  | Equity | Common Stock, par value $0.00001 per share | 457(o) |  |  |  |  |  |  |  |  |  |
|  | Equity | Pre-funded warrants to purchase Common Stock | 457(o) |  |  |  |  |  |  |  |  |  |
|  | Equity | Common stock, par value $0.00001 per share, issuable upon exercise of Pre-Funded Warrants |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Fees to be <br>Paid<sup>1</sup> | Unallocated (Universal) Shelf |  | 457(o) |  |  | $49907450.00 | 0.0001381 | $6892.22 |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Fees<br>Previously <br>Paid |  |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Carry Forward Securities | &nbsp;&nbsp;&nbsp;Carry Forward Securities | &nbsp;&nbsp;&nbsp;Carry Forward Securities | &nbsp;&nbsp;&nbsp;Carry Forward Securities | &nbsp;&nbsp;&nbsp;Carry Forward Securities | &nbsp;&nbsp;&nbsp;Carry Forward Securities | &nbsp;&nbsp;&nbsp;Carry Forward Securities | &nbsp;&nbsp;&nbsp;Carry Forward Securities | &nbsp;&nbsp;&nbsp;Carry Forward Securities | &nbsp;&nbsp;&nbsp;Carry Forward Securities | &nbsp;&nbsp;&nbsp;Carry Forward Securities | &nbsp;&nbsp;&nbsp;Carry Forward Securities | &nbsp;&nbsp;&nbsp;Carry Forward Securities |
| &nbsp;&nbsp;&nbsp;Carry Forward Securities |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $49907450.00 |  | $6892.22 |  |  |  |  |
|  |  | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: |  |  |  | $0.00 |  |  |  |  |
|  |  | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  |  | $0.00 |  |  |  |  |
|  |  | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  |  | $6892.22 |  |  |  |  |

---

#### Offering Note

<sup>1</sup> The amount to be registered consists of up to $49,907,450.00 of an indeterminate amount of common stock, par value $0.00001 per share (the "Common Stock"), pre-funded warrants to purchase shares of the Company's stock ("Pre-Funded Warrants") and shares issuable upon the exercise of Pre-Funded Warrants. Any securities registered hereunder may be sold separately or together with other securities registered hereunder. Pursuant to Rule 416 under the Securities Act of 1933, as amended, this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or pursuant to anti-dilution provisions of any of the securities. Separate consideration may or may not be received for securities that are issuable upon conversion, exercise or exchange of other securities. 

The proposed maximum offering price per security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act of 1933, as amended.

Includes such indeterminate amount of common stock as may be issued from time to time upon exercise of Pre-Funded Warrants registered hereby, as the case may be.

Pre-Funded Warrants may be sold separately or together with any of the securities registered hereby and may be exercisable for shares of common stock registered hereby. Because the Pre-Funded Warrants will provide a right only to purchase such securities offered hereunder, no additional registration fee is required.

------

Table 2: Fee Offset Claims and Sources ☑ Not Applicable

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Registrant<br>or Filer<br>Name | Form<br>or<br>Filing<br>Type | File<br>Number | Initial<br>Filing<br>Date | Filing<br>Date | Fee<br>Offset<br>Claimed | Security<br>Type<br>Associated<br>with Fee<br>Offset<br>Claimed | Security<br>Title<br>Associated<br>with Fee<br>Offset<br>Claimed | Unsold<br>Securities<br>Associated<br>with Fee<br>Offset<br>Claimed | Unsold<br>Aggregate<br>Offering<br>Amount<br>Associated<br>with Fee<br>Offset<br>Claimed | Fee<br>Paid<br>with<br>Fee<br>Offset<br>Source |
| &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) | &nbsp;&nbsp;&nbsp;Rules 457(b) and 0-11(a)(2) |
| &nbsp;&nbsp;&nbsp;Fee Offset Claims | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| &nbsp;&nbsp;&nbsp;Fee Offset Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| &nbsp;&nbsp;&nbsp;Rule 457(p) | &nbsp;&nbsp;&nbsp;Rule 457(p) | &nbsp;&nbsp;&nbsp;Rule 457(p) | &nbsp;&nbsp;&nbsp;Rule 457(p) | &nbsp;&nbsp;&nbsp;Rule 457(p) | &nbsp;&nbsp;&nbsp;Rule 457(p) | &nbsp;&nbsp;&nbsp;Rule 457(p) | &nbsp;&nbsp;&nbsp;Rule 457(p) | &nbsp;&nbsp;&nbsp;Rule 457(p) | &nbsp;&nbsp;&nbsp;Rule 457(p) | &nbsp;&nbsp;&nbsp;Rule 457(p) | &nbsp;&nbsp;&nbsp;Rule 457(p) |
| &nbsp;&nbsp;&nbsp;Fee Offset Claims | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| &nbsp;&nbsp;&nbsp;Fee Offset Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |

---

------

Table 3: Combined Prospectuses ☑ Not Applicable

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Security <br>Type | Security <br>Class Title | Amount of Securities <br>Previously Registered | Maximum Aggregate <br>Offering Price of<br>Securities Previously<br>Registered | Form Type | File<br>Number | Initial<br>Effective<br>Date |
| &nbsp;&nbsp;&nbsp;N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |

---